

# JMS

*Journal of Morphological Sciences*

# Journal of Morphological Sciences

Current Archives About

## Current Issue

Vol 6 No 3 (2023): JMS



ISSN 2545-4706

<https://doi.org/10.55302/JMS>

<https://doi.org/10.55302/JMS2363>

Published: 2023-12-27

## Articles

### LOCALLY-ADVANCED BREAST CANCER IN A MALE PATIENT: A CASE REPORT

Nedjati Jakupi, Stojan Velkov, Despot Despotovski, Ljubica Atanasova

1-3



### OUR EXPERIENCE WITH INVASIVE SKIN CARCINOMA OF THE SKULL TREATED WITH A ROTATIONAL FLAP

Ana Tomevska, Mikjun Mikjunovikj, Zoran Bitrakov, Biljana Trajanoska, Slavco Ivanoski, Ana Trimoska Radeska, Emilija Mikjunovikj, Ace Dodevski

4-9



### THE INFLUENCE OF ACUTE DECOMPENSATION ON ONE-YEAR SURVIVAL AND MORTALITY IN PATIENTS WITH LIVER CIRRHOSIS

Elena Curakova Ristovska, Magdalena Genadieva-Dimitrova, Beti Todorovska, Kalina Grivceva Stardelova, Ivan Rankovich, Vladimir Milivojevich, Ante Bogut, Georgi Janevski

10-20



## **NEPHROPROTECTIV EFFECTS OF CANDESARTAN ON DIABETIC NEPHROPATHY IN RATS**

Jasmina Trojancanec, Kristina Pavlovska, Kalina Gjorgjievska, Nikola Kolovchevski, Emilija Shikole, Bojan Labachevski, Aleksandar Nikodinovski, Igor Kikerkov, Dimche Zafirov 21-33

 PDF

## **ACUTE MESENTERIC VENOSUS THROMBOSIS IN A PREGNANT WOMAN**

Aleksandra Eftimova, Ana Kocevaska, Anamarija Shpisikj Pushevaska, Jasmina Chelebieva 34-38

 PDF

## **OBESITY AS A RISK FACTOR FOR ENDOMETRIAL PATHOLOGICAL CHANGES**

Ana Kocevaska, Anamarija Shpisikj Pushevaska, Zoran Ilievski, Aleksandra Eftimova Kitanova, Kristina Skeparovska 39-45

 PDF

## **COMPARISON OF THE VALUES OF EFT (External Fixation Time) IN THE TREATMENT OF LOWER LEG OPEN FRACTURES AND NON-UNIONS WITH THE METHOD OF COMPRESSION-DISTRACTION OSTEOSYNTHESIS BY ILIZAROV**

Ognen Sheshoski, Slavcho Stojmenski, Nenad Atanasov, Simon Trpeski, Petar Miloshevski 46-55

 PDF

## **THE ROLE OF HIGH-RESOLUTION CT IN THE DETECTION AND DIFFERENTIATION OF PULMONARY CHANGES BETWEEN UIP AND NSIP PNEUMONIA**

Kristina Dimitrijevikj, Nadica Mitreska, Biljana Prgova-Veljanova, Sonja Nikolova, Milkica Pashoska 56-67

 PDF

## **AMYAND'S HERNIA -A RARE CASE OF RIGHT -SIDED IN INGUINAL HERNIA**

Velimir Shumenkovski, Dimitar Arnaudov, Bojan Trenchikj, Svetozar Antovikj, Ljubomir Ognjenovikj, Ognen Kostovski, Goce Volchevski, Dragan Hadzi Manchev, Gjorfji Trajkovski 68-71

 PDF

## **CASE REPORT OF ANGELMAN SYNDROME- A CHILD WITH PATHOGENIC VARIANT c.678dup, p.(Leu227iLefster4) IN THE EXON 7 OF UBEZA GENE**

Danilo Nonkulovski, Aspazija Sofijanova, Sonja Bojadzieva, Ilija Kirovski, Olivera Viktor Jordanova 72-77

 PDF

## **BIODISTRIBUTION STUDY OF 188Re-HEDP AS A RADIOPHARMACEUTICAL FOR BONE PAIN PALLIATION**

Toni Tripunoski, Domokos Mathe, Lajos Balog, Ana Ugrinska, Maja Chochevska, Sinisa Stojanoski, Nikolina Bozinovska, Nevena Manevska, Anamarija Jankulovska, Daniela Popgjorceva 78-84

 PDF

## **HIGH -RESOLUTION CT PULMONARY CHANGES IN PATIENTS WITH CYSTIC FIBROSIS USING BHALLA SCORE SYSTEM CORRELATED WITH CLINICAL PARAMETERS**

Kristina Dimitrijevikj, Nadica Mitreska, Violeta Vasilevska-Nikodinovska

85-98

 PDF

## **ADRENAL GLAND TLR EXPRESSION IN ApoE DEFICIENT HOMOZYGOUS (ApoE KO-/-) MICE WITH IMPAIRED THYROID FUNCTION**

Toni Tripunoski, Sasho Panov, Jasmina Dimitrova Shumkovska, Slavica Josifovska, Irena Kostadinova Petrova, Ana Ugrinska, Sinisa Stojanoski, Nevena Manevska, Verdi Stanojevic, Bojana Stoilovska Rizova, Daniela Popgjorceva

99-108

 PDF

## **ACADEMIC BACKGROUND OF THE PROFESSIONS ELIGIBLE FOR VOCATIONAL TRAINING IN MEDICAL BIOCHEMISTRY IN THE REPUBLIC OF NORTH MACEDONIA**

Jasna Bogdanska, Katerina Tosheska Trajkovska, Sonja Topuzovska

109-119

 PDF

## **FINANCIAL BARRIERS AND ACCESSIBILITY OF HEALTH SERVICES AMONG PATIENTS WITH NON-COMMUNICABLE DISEASES IN URBAN AND RURAL AREAS IN THE PELAGONIAN REGION**

Svetlana Popovska Kljuseva, Vesna Velikj Stefanovska, Dragan Kochinski

120-128

 PDF

## **INFORMED CONSENT IN GENETIC REASEARCH**

Ljupco Chakar, Aleksandar Stankov, Goran Pavlovski, Natasha Bitoljanu, Viktorija Belakaposka Srpanova, Ana Ivcheva, Rosica Siamkouri, Zlatko Jakjovski

129-134

 PDF

## **TRAUMATIC NECK INJURIES IDENTIFIED BY CONVENTIONAL X-RAY IMAGING-AN AUTOPSY CASE REPORT**

Renata Jankova, Zoran Mitrevski

135-139

 PDF

## **SERUM ANTI-OXLDL ANTIBODIES IN PATIENTS WITH ANGIOGRAPHICALLY CONFIRMED CORONARY ARTERY DISEASE**

Katerina Tosheska-Trajkovska, Irena Kostovska, Melda Emin, Hristina Ampova, Nikola Manev, Zan Zimbakov, Coskun Kerala, Jasna Bogdanska, Sonja Topuzovska

140-147

 PDF

## **PREPARATION AND IN VITRO STABILITY STUDY OF 188Re-HEDP AS A BONE SEEKING RADIOPHARMACEUTICAL**

Toni Tripunoski, Domokos Mathe, Lajos Balog, Ana Ugrinska, Maja Chochevska, Sinisha Stojanoski, Elena Stanojevska, Nevena Manevska, Toni Grozdanovski, Daniela PopGjorceva

148-156

 PDF

## **SPONTANEOUS VISUAL RECOVERY FOLLOWING COMBINED CENTRAL RETINAL VEIN AND CILIORETINAL ARTERY OCCLUSION – CASE REPORT**

Natasa Trpevska Sekerinov, Andrijana Petrusevska, Emilija Gjosevska Dastevska

157-162

 PDF

## **RECURRENT CENTRAL VENOUS RETINAL OCCLUSION, CLINICAL FEATURES AND TREATMENT OUTCOME**

Jana Nivicka Kjaeva, Natasa Trpevska Sekerinov, Gazmend Mehmeti, Andrijana Petrusevska

163-169

 PDF

## **BILATERAL CONGENITAL CATARACT IN A NEWBORN- LITERATURE REVIEW AND CASE REPORT**

Igor Isjanovski, Stefan Pandilov, Emilija Gjosevska Dashtevska

170-175

 PDF

## **DIAGNOSTIC AND THERAPEUTIC MODALITIES IN THE MANAGEMENT OF OPTIC DISC PIT MACULOPATHY- CASE REPORT AND LITERATURE REVIEW**

Stefan Pandilov, Natasa Trpevska Sekerinov

176-182

 PDF

## **CRANBERRY, A POTENTIAL ALTERNATIVE TREATMENT FOR URINARY TRACT INFECTIONS**

Liljana Labacevska Gjatovska, Marko Kostovski, Maja Jurhar-Pavlova, Danica Kovacheva-Trpkovska, Radomir Jovchevski, Kiril Mihajlov, Tatjana Grdanoska, Bojan Labachevski, Kristina Pavlovska

183-189

 PDF

## **ANTIMICROBIAL RESISTANCE IN GRAM NEGATIVE BACILLI ISOLATED FROM BLOOD CULTURE**

Danica Kovacheva-Trpkovska, Marko Kostovski, Radomir Jovcevski, Liljana Labacevska-Gjatovska, Kiril Mihajlov, Tatjana Grdanoska, Igor Trpkovski, Branka Petrovska-Basovska, Blerta Mehmeti

190-197

 PDF

## **THROMBOCYTOPENIA ASSOCIATED WITH HEPATITIS B VIRUS INFECTION-CASE REPORT**

Haris Sulejmani, Nenad Bogdanovski, Ivana Zafirova, Svetlana Krstevska Balkanov

198-202

 PDF

## **COMBINING PROSTATE HEALTH INDEX AND mpMRI DATA (MRI SPECTROSCOPY) TO MANAGE PI-RADS LESIONS AND REDUCE EXCESSIVE BIOPSY, A SINGLE CENTER STUDY**

Toni Krstev, Ivica Stojanoski, Lazar Ilievski, Nerhim Tufekchioski, Biljana Prgova-Veljanova, Masha Kostova, Olivera Stojcheva-Taneva, Jasmina Trojcanec, Stefan Milenkovski

203-216

 PDF



**DIAGNOSTIC PERFORMANCE OF PROSTATE HEALTH INDEX (PHI) IN PREDICTING PROSTATE CANCER ON PROSTATE BIOPSY; A SINGLE CENTER STUDY**

Toni Krstev, Ivica Stojanoski, Lazar Ilievski, Nerhim Tufekchioski, Olivera Stojcheva-Taneva, Jasmina Trojancanec, Cvetanka Volkanovska Iljevska

222-233



**THE ROLE OF TGF- $\beta$ 1 IN THE DEVELOPMENT OF DIABETIC NEPHROPATHY EXPERIMENTALLY INDUCED BY STREPTOZOTOCIN AND THE NEPHROPROTECTIVE EFFECTS OF CANDESARTAN**

Jasmina Trojancanec, Kristina Pavlovska, Emilija Shikole, Nikola Kolovchevski, Bojan Labachevski, Aleksandar Nikodinovski, Krume Jakjovski, Igor Kikerkov, Marija Petrusevska, Panche Zdravkovski, Dimche Zafirov

234-245



**BIOFILM IN CHRONIC DIABETIC FOOT ULCER-CASE REPORT**

Julija Mitrova Telenta, Liljana Labacevska Gjatovska, Marko Kostovski, Maja Dimova, Ivana Dohceva Karajovanov, Suzana Nikolovska, Silvija Duma, Hristina Breshkovska, Nikola Panovski

246-250



[View All Issues >](#)

**Information**

[For Readers](#)

[For Authors](#)

[For Librarians](#)

**Journal of Morphological Sciences** is an official journal of the **Macedonian Association of Anatomists**, published twice or three times a year in English.

# Journal of Morphological Sciences

[Current](#) [Archives](#) [About](#)

[Home](#) / [Editorial Team](#)

## ***Editor- in-Chief***

Biljana Zafirova

## ***Deputy editors***

Biljana Trpkovska

## ***Editorial Council***

Biljana Zafirova

Nikola Jankulovski

Niki Matveeva

Sonja Topuzovska

Beti Zafirova Ivanovska

Viktorija Jovanovska

Goran Dimitrov

Sunchica Petrovska

Jasna Bogdanska

Elena Kjosevska

Nikola Labachevski

Sonja Bojadzieva

---

***Editorial Office***

Anamarija Paunkoska

Lenche Danevska

Biljana Narashanova - secretary

***International Editorial Board***

Ace Dodevski, R. North Macedonia

Biljana Bojadzieva Stojanoska, R. NorthMacedonia

Elizabeta Chadikovska, R. North Macedonia

Jane Netkovski, R. North Macedonia

Katerina Kubelka Sabit, R. North Macedonia

Lazo Noveski, R. North Macedonia

Slavica Kostadinova Kunovska, R. North Macedonia

Vesna Janevska, R. North Macedonia

Vladimir Popovski, R. North Macedonia

Jasmina Trojachanec, R. North Macedonia

Sanja Mancevska, R. North Macedonia

Bruno Nikolovski, R. North Macedonia

Jasna Halilovic, Bosnia and Herzegovina

Silvia Mladenova, Bulgaria

Monika Urbaniak, Poland

Ivica Grkovic, Croatia

Simon Pkhrikyan, Armenia



Igor Sladojevic, Bosnia and Herzegovina

Ljiljana Tadic, Bosnia and Herzegovina

Biljana Srdic, Serbia

Dusica Maric, Serbia

Ivana Kavecic, Serbia

Zivka Eri, Serbia

Ljiljana Vasovic, Serbia

Mirela Eric, Serbia

Slobodan Vlajkovic, Serbia

Zoran Pesic, Serbia

Filip Vukmirovic, Montenegro

Mileta Golubovic, Montenegro

Vitaly Gargin, Ukraine

Iva Petkovska, USA

Jadranka Stojanovska, USA

## Information

[For Readers](#)

[For Authors](#)

[For Librarians](#)

**Journal of Morphological Sciences** is an official journal of the **Macedonian Association of Anatomists**, published twice or three times a year in English.

## DIAGNOSTIC PERFORMANCE OF PROSTATE HEALTH INDEX (PHI) IN PREDICTING PROSTATE CANCER ON PROSTATE BIOPSY; A SINGLE CENTER STUDY

Toni Krstev<sup>1</sup>, Ivica Stojanoski<sup>1,2</sup>, Lazar Ilievski, Nehrim Tufekchioski,<sup>1</sup>,

Olivera Stojceva-Taneva<sup>3</sup>, Jasmina Trojancanec<sup>4,5</sup>, Cvetanka Volkanovska Ilijevska<sup>5,6</sup>

<sup>1</sup>Department of Urology, City General Hospital 8<sup>th</sup> of September Skopje, North Macedonia

<sup>2</sup>Faculty of Medicine, Goce Delchev University, Shtip, North Macedonia

<sup>3</sup>Clinic of Nephrology, Skopje, North Macedonia

<sup>4</sup>Department of Preclinical and Clinical Pharmacology and Toxicology, Skopje, North Macedonia

<sup>5</sup>Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia

<sup>6</sup>University Clinic for Endocrinology, Diabetes and Metabolic Disorders, Skopje, North Macedonia

### Abstract

The Prostate Health Index (PHI) is a new test combining total, free and (-2)proPSA into a single score. It was recently approved by the FDA and is now commercially available in the U.S., Europe and Australia. Our aim is to investigate whether PHI improves specificity for detecting clinically significant prostate cancer and can help to reduce prostate cancer biopsies.

We examined 100 men age 50 years or older with prostate specific antigen 4 to 10 ng/ml („gray zone,,) and normal digital rectal examination with suspected prostate cancer who had undergone biopsies and were divided into a benign and malignant group. In this population we compared the performance of prostate specific antigen, % free prostate specific antigen, (-2)proPSA and PHI to predict biopsy results and, specifically, the presence of clinically significant prostate cancer using multiple criteria.

We found statistically significantly increased levels of -2proPSA, PHI and PSA and decreased levels of %freePSA in patients diagnosed with prostate cancer by prostate biopsy vs. patients with benign prostatic conditions (median values: -2proPSA: 28.3 vs. 20.11 ng/l, PHI: 73.04 vs. 30.5, total PSA: 7.3 vs. 6.48 ng/ml and %free PSA: 17.06 vs. 25.62%). On receiver operating characteristic analysis PHI had the highest AUC for overall prostate cancer (AUCs PHI 0.954, percent free prostate specific antigen 0.345, (-2)proPSA 0.753 and prostate specific antigen 0.656). The optimal cut-off for PHI in the study population was 42.8 with sensitivity of 85.7% (95% CI: 54.8-90.6) and specificity of 86.1% (CI 95%, 0.913-0.995). Whereas, in the tPSA for cut-off 6.54 sensitivity is 61.9 and specificity 59.5, respectively. The Prostate Health Index was significantly higher in men with Gleason 7 or greater. In our study for the PHI levels (36-54.99) only 23.08% of patients had Gleason score  $\geq 7$ . In patients with PHI levels  $>55$ , 76.92% of patients had Gleason score  $\geq 7$ .

The new PHI test outperforms its individual components of total, free and (-2)proPSA for the identification of clinically significant prostate cancer. PHI may be useful as part of a multivariable approach to reduce prostate biopsies and overdiagnosis.

**Keywords:** PHI; prostate cancer, early detection, prostate biopsy.

### Introduction

Prostate cancer (PCa) is the second most common cancer in men worldwide [1]. According to the latest WHO data published in 2020 Prostate Cancer Deaths in North Macedonia reached 259 or 1.13% of total deaths.

The age adjusted Death Rate is 17.47 per 100.000 of population and ranks North Macedonia on the 77<sup>th</sup> place in the world [2]. Prostate-specific antigen (PSA) is the most widely-known prostate specific biomarker. The total level of prostate-specific antigen (tPSA) has long been used as a tumor marker for prostate cancer (PCa). T

total PSA has a limited sensitivity and specificity for PC detection. Its low specificity led to an excessive number of prostate biopsies and unnecessarily high levels of treatment (overtreatment), while its low sensitivity meant a decrease in detection of low-grade PCa. [3, 4].

However, it has limited sensitivity and specificity in diagnosing PCa. In addition to PCa, a large number of cases with elevated total PSA (tPSA) is due to benign prostate conditions such as benign prostate hyperplasia and chronic prostatitis. Other factors that also affect tPSA levels include biological variation, urinary tract infection, prostatic manipulation or ejaculation [5].

Because of these limiting factors, it is almost impossible to find a universal appropriate tPSA cut-off for the diagnosis of prostate cancer. Prostate biopsy is still the gold standard for confirmation of PCa. However, only about 25- 30% of men who have had biopsies for elevated tPSA levels were found to have cancer, while the majority had false-positive tests and underwent unnecessary biopsies. Furthermore, 15% of biopsies in men with lower levels of tPSA had detected cancer [6].

In last decades, several PSA isoforms have been identified that may increase the specificity for prostate cancer[7].

In particular, the (-2) form of proPSA ('p2PSA') has become commercially available, with improved performance over either total or free PSA for prostate cancer detection on biopsy [8].

The Prostate Health Index (PHI) combines all three forms (total PSA, free PSA and p2PSA) into a single score that can be used to aid in clinical decision-making [9].

PHI is calculated using the following formula:  $([-2]proPSA/free PSA) \times \sqrt{PSA}$ .

PHI, developed by Beckman Coulter, Inc., was introduced as a new marker for improving the clinical sensitivity and specificity in prostate cancer diagnosis particularly for men with borderline raised tPSA levels and DRE not suspicious of the cancerous state.

The categories of PHI suggested by the manufacturer and supported by many investigators include: very low risk (0-26.99), low risk (27-35.99), moderate risk (36-54.99), and high risk (55+) categories. In most studies, the diagnostic performance of PHI was evaluated at limited tPSA range of 4-10ng/ml.

A non-negligible proportion of patients with tPSA beyond this range may not have PCa. In view of this, our study aimed to further evaluate the diagnostic performance of PHI in Macedonian men with a wider concentration range of tPSA levels.

## **Material and methods**

### **Study design and population**

This is a prospective observational non-randomized study from 2018 to 2019 conducted at General City Hospital 8 th September in Skopje, R.of North Macedonia. The study included consecutive men above 50 y/o, with negative DRE, undergoing transrectal ultrasound-guided (TRUS) prostate biopsy for suspected PCa with tPSA level of 4-10ng/ml. Men receiving 5- $\alpha$ -reductase inhibitors, evidence of acute prostatitis, urinary tract infection and those with previous history of prostatic surgery for any prostatic condition were excluded from this study.

Blood samples were drawn prior to TRUS biopsy. Patients then underwent TRUS biopsy according to standardized protocol; with a minimum of 12 biopsy cores taken. PCa was identified and graded according to the 2005 consensus conference of the International Society of Urological Pathology.

The primary endpoint of this study was to directly compare the diagnostic accuracy of %p2PSA and PHI (index tests) in the detection of prostate cancer in comparison to the tPSA and %fPSA (standard tests). The number of potentially avoidable biopsies if these tests were used as a guide for prostate biopsy decision was calculated.

Patients were stratified into two groups: with prostate cancer and no cancer group.

### *Biochemical analysis*

Serum samples for tPSA, fPSA and p2PSA were collected and centrifuged within two hours of collection, aliquoted and stored at -70°C until analysis. Testing was performed on Access2 automated immunoassay analyser (Beckman Coulter, CA, USA), using Hybritech calibrators, controls, and reagents..

%fPSA (fPSA/ tPSAx100), %p2PSA (p2PSA/fPSAx100) and PHI ( $[\text{p2PSA}/\text{fPSA}] \times \sqrt{\text{tPSA}}$ ) were then obtained via calculation.

### Statistical analysis

Statistical analyses were performed using SPSS v.24 software. Continuous and categorical variables were summarised by the median and interquartile range (IQR) for skewed data and frequency measures, respectively. Mann-Whitney U test was used for comparisons of continuous variables and Chi-Square test was used for comparisons of categorical variables. Medcalc v.17.0.4 software was used to plot receiver operating characteristic (ROC). Predictive accuracy was quantified as the area under the receiver operating characteristic curve (AUC). The AUC between variables were compared using Delong's method. A two-sided p-value <0.05 was considered statistically significant in all analyses.

### Ethics

This study was approved by the research ethics committee of faculty of Medicine, University of Ss. Cyril and Methodius Skopje, Republic of North Macedonia.

### Results

100 patients consented to the study. 21% had prostate cancer, 79% are without cancer. The median age was  $69.2 \pm 6.8$  years. No statistically significant difference was noted in the age between patients with or without PCa ( $69.8 \pm 7.2$  vs  $70.8 \pm 4.8$  y/o,  $p=0.24$ ). (Table 1).

**Table 1.** Correlation between age and PSA

	Age (y/o)		p value
	mean $\pm$ SD	min- max	
PCa	$70.8 \pm 4.8$	61 – 77	t=1.18
no PCa	$69.8 \pm 7.2$	51 – 85	p=0.24

no PCa (benign prostatic conditions); t(Student t-test)  
PCa (prostate cancer)

**Table 2.** Basic clinical characteristics of the study population

	Descriptive Statistics		
	mean $\pm$ SD	min- max	median (IQR)
PSA	$6.66 \pm 1.7$	4.02 – 10	
PHI	$42.01 \pm 26.1$	8.8 – 133	34.93 (27.51 – 45.8)
fpsa	$1.82 \pm 1.1$	0.36 – 6.81	1.47 (1.17 – 2.36)
%fpsa	$26.75 \pm 13.8$	0.81 – 78.89	24.02 (16.34 – 34.34)
pro2psa	$27.03 \pm 20.9$	5.41 – 156.97	22.25 (14.03 – 31.41)
%pro2psa	$1.65 \pm 0.9$	0.4 – 5	1.4 (1.045 – 1.88)

The PSA in both groups was  $6.66 \pm 1.7$ . PSA was  $7.33 \pm 1.6$  ng/ml in the group with PCa, and  $6.48 \pm 1.6$  ng/ml in the group with no PCa. The difference between them was 0.85 ng/ml and it is slightly statistically significant,  $p=0.039$ . %p2PSA and PHI values were significantly higher in patients with PCa. Conversely, no statistically significant difference was noted in %fPSA and fPSA values between patients with and without PCa.

PHI levels in patients with PCa and patients without PCa are statistically more significant than tPSA ( $p<0.0001$ ). PHI was significantly higher in patients with PCa. PHI had mean values  $79.01 \pm 33.4$  and  $32.18 \pm 10.4$ , for the groups with PCa and without PCa respectively, and median values of 73.04 and 30.5 respectively.

**Table 3.** Comparison of PSA, fPSA, %fPSA, %p2PSA, p2PSA and PHI between the two groups of patients

	PSA (ng/ml)			p value
	mean $\pm$ SD	min- max		
PCa	$7.33 \pm 1.6$	4.71 – 9.97		t=2.1
no PCa	$6.48 \pm 1.6$	4.02 – 10		*p=0.039
	Fpsa			p value
	mean $\pm$ SD	min- max	median (IQR)	
PCa	$1.56 \pm 0.9$	0.54 – 3.5	1.24 (0.95 – 1.7)	Z=1.5
no PCa	$1.89 \pm 1.13$	0.36 – 6.81	1.56 (1.2 – 2.37)	p=0.12
	%fpsa			p value
	mean $\pm$ SD	min- max	median (IQR)	
PCa	$21.92 \pm 12.5$	7.8 – 44.85	17.06 (12.93 – 28.7)	Z=2.17
no PCa	$28.04 \pm 13.9$	0.81 – 78.89	25.62 (18.4 – 34.39)	*p=0.03
	%p2psa			p value
	mean $\pm$ SD	min- max	median (IQR)	
PCa	$2.95 \pm 1.1$	1.5 – 5	2.59 (2.21 – 3.9)	Z=6.3
no PCa	$1.30 \pm 0.4$	0.4 – 2.57	1.23 (0.95 – 1.6)	***p=0.00000
	p2psa (ng/ml)			p value
	mean $\pm$ SD	min- max	median (IQR)	
PCa	$44.95 \pm 34.8$	13.04 – 156.97	28.3 (25.72 – 60.7)	Z=3.55
no PCa	$22.27 \pm 11.5$	5.41 – 52.21	20.11 (13.47 – 28.49)	***p=0.000385
	PHI			p value
	mean $\pm$ SD	min- max	median (IQR)	
PCa	$79.01 \pm 33.4$	36.8 – 133.3	73.04 (48.31 – 103.1)	Z=6.4
no PCa	$32.18 \pm 10.4$	8.8 – 58.82	30.5 (25.4 – 38.71)	***p=0.00000


no PCa (no prostate cancer)

Z(Mann-Whitney U Test);

\*\*\*p<0.0001

PCa (prostate cancer)

**Graph 1.** Whisker plots of PSA and PHI in the two groups



**Table 4.** Different levels of PHI divided in 4 groups: 0-26.99, 27-35.99, 36-54.99 and 55+ was analyzed in the patients with and without PCa.

PHI				p value	difference between two proportions
	n	PCa n (%)	no PCa n (%)		
0 – 26.99	23	0 (0.00)	23 (29.11)	X <sup>2</sup> =52.8 ***p=0.000	**p=0.0048
27 – 35.99	30	0 (0.00)	30 (37.97)		***p=0.0007
36 – 54.99	30	7 (33.33)	23 (29.11)		p=0.7
55>	17	14 (66.67)	3 (3.8)		***p=0.0000

no PCa (no prostatic cancer)  
square); \*\*p<0.01, \*\*\*p<0.0001  
PCa (prostatic cancer)

X<sup>2</sup> (Pearson Chi-

In the group with very low risk 0-26.99 only 23 patients (29.11%) were with no evidence of PCa. And 30 patients (37.97%) without PCa were in the group with low risk. In the group with moderate level of PHI values 36-54.99 only 7 (33.33%) were with PCa and 23 (29.11%) without PCa. Finally, in the PHI group with the highest level (55+), 14 (66.67) patients were with PCa compared to only 3 (3.8%) with no evidence of PCa. There was a statistically significant difference between two groups with and without PCa, p<0.0001.

**Table 5.** Univariate and multivariate logistic regression analysis including all the prostate markers and age

Controls vs Prostate cancer				
	Univariate		Multivariate	
	p value	OR (95% IP)	p value	OR (95% IP)
age	0.239	1.046(0.971-1.126)		
PSA	*0.043	1.344(1.0099-1.791)		
PHI	***0.000	1.164(1.082-1.253)	***0.000	1.162(1.079-1.232)
fpsa	0.235	0.723(0.424-1.235)		
%fpsa	0.074	0.961(0.92-1.004)		
p2psa	**0.001	1.027(1.027-1.102)		
%p2psa	***0.000	2.25(1.79-8.81)	***0.000	2.13(1.56-7.60)

\*p<0.05, \*\*\*p<0.0001

Univariate and multivariate logistic regression analysis were used to accurate the predictive value of PSA and its various parameters. Univariate analysis of the various parameters (PSA, PHI, p2PSA, %p2PSA) showed that PHI and % p2PSA were the most accurate predictors of PCa in the study population. (p=0.043, p<0.0001, p=0.001 and p<0.0001, respectively).

**Table 6.** AUC including all the prostate markers (PSA, fPSA,%fPSA, p2PSA, %p2PSA and PHI)

	AUC	Std. Error <sup>a</sup>	Asymptotic Sig. <sup>b</sup>	95% Confidence Interval	
				Lower Bound	Upper Bound
<b>PSA</b>	0.656	0.063	0.029	0.532	0.780
<b>fpsa</b>	0.390	0.071	0.121	0.250	0.529
<b>%fpsa</b>	0.345	0.075	0.029	0.197	0.493
<b>p2psa</b>	0.753	0.057	0.000	0.642	0.865
<b>%p2psa</b>	0.948	0.023	0.000	0.904	0.992
<b>PHI</b>	0.954	0.021	0.000	0.913	0.995

In the accuracy analysis, the AUCs of tPSA and its various parameters %fPSA, %p2PSA and PHI were 0.656, 0.345, 0.948 and 0.954, respectively. PHI was the most accurate predictor of PCa in the study population. There was a significant difference between the AUCs of PHI and tPSA. AUC (Area Under the Curve) for tPSA - 0.656 (AUC=0.656, CI 95% 0.532-0.780), compared to AUC (Area Under the Curve) for PHI - 0.954 (AUC=0.954, CI 95% 0.913-0.995).


**Table 7.** Cut-off values, sensitivity and specificity including all the prostate markers (PSA, fPSA,%fPSA, p2PSA, %p2PSA and PHI)

variable	Area	p value	received cut off values	chosen cut off values	Sn	Sp
PSA	0.656 (0.532 – 0.780)	0.029	6.54		61.9	59.5
fpsa	0.390 (0.250 – 0.529)	0.121	1.335		38.1	39.2
%fpsa	0.345 (0.197 – 0.493)	0.029	21.91		33.3	32.9
p2psa	0.753 (0.642 – 0.865)	0.000	26.05		66.7	65.8
%p2psa	0.948 (0.904 – 0.992)	0.000	1.745		85.7	86.1
				1.36	100	63.29
				2.15	76.19	94.94
PHI	0.954 (0.913 – 0.995)	0.000	42.8		85.7	86.1
				26.99	100	29.11
				35.99	100	68.35
				54.99	66.67	96.2


The optimal cut-off for PHI in this study population was 42.8 with sensitivity of 85.7% (95% CI: 54.8-90.6) and specificity of 86.1% (CI 95%, 0.913-0.995). Whereas, the tPSA for cut-off 6.54 sensitivity is 61.9 and specificity 59.5, respectively.

We also tested the manufacturer’s recommended PHI range (taken from the manufacturer’s package insert) into our study population. For PHI value below 26.99, chances for prostate biopsy will be negative in more than 90% as stated in the manufacturer insert.

Our study findings were in agreement with the manufacturer for PHI below 26.99. As the PHI values increased, the percentage of PCa and GS >7 cases detected correspondingly increased. In the high-risk group (PHI >35.99), 50% of cases that underwent prostate biopsy were positive.



**Graph 2.** Sensitivity and specificity for PSA



**Graph 3.** Sensitivity and specificity for PHI



**Table 8.** Comparison of PHI values divided in two groups between patients with Gleason score less and more than 7

PHI	Gleason			p value
	n	< 7 n (%)	≥ 7 n (%)	
36 – 54.99	7	4 (50)	3 (23.08)	X <sup>2</sup> = p=0.
>55	14	4 (50)	10 (76.92)	
total	21	8	13	

X<sup>2</sup> (Pearson Chi-square)

**Table 9.** Correlation between Gleason score and PHI

Gleason	PHI			p value
	mean ± SD	min- max	median (IQR)	
<7	74.29 ± 36.4	41.89 – 133.3	63.61(45.89-100.1)	Z=0.47 p=0.00638
≥7	81.91 ± 32.5	36.8 – 131.82	79.43(59.4-103.1)	
	79.01 ± 33.4	36.8 – 133.3	73.04(48.31-103.1)	

Z(Mann-Whitney U Test)

Among the 21 patients with positive biopsy, a mean age of  $70.8 \pm 4.8$  years (range: 61 to 77) (Table 1). A clinically significant PCa (Gleason score 7 (3 + 4) or higher) was observed in 13 patients (61.9%). PHI preserved a significant association with the presence of csPCa, respectively. PHI was higher in csPCa 79.43(59.4-103.1) vs 63.61(45.89-100.1) (  $p=0.00638$ ).

The optimal cut-off for the identification of csPCa was 42.7 with sensitivity: 85.7% and specificity 86.1%. If biopsy was restricted to patients with  $PHI \geq 42.7$ , 33.3% of biopsy could be avoided, but three csPC patients were missed. Furthermore, if biopsy was restricted to patients with  $PHI \geq 42.8$ , up to 50% of biopsy could be avoided with only one csPC patient being missed.

## Discussion

The usefulness of PHI was evaluated. Our findings support previous results regarding that biomarker. Large studies from the U.S., Europe and Asia have uniformly demonstrated that PHI improves specificity and provides a greater net benefit for prostate cancer detection compared to total and free PSA. [10].

Deciding when to biopsy a man with non-suspicious DRE findings and tPSA in the 4–10 ng/ml range (gray zone) can be challenging, because two-thirds of such biopsies are typically found to be benign. Currently, PSA is widely used for PCa screening, but the limitations of PSA as a biomarker for PCa detection have been well demonstrated. It is necessary to distinguish PCa from benign prostatic disease and to clarify the aggressiveness of cancers, but PSA cannot completely predict the presence and biological behavior of PCa. [11].

The early detection of PCa using PSA results in a large number of negative biopsies and a high proportion of patients diagnosed with clinically low aggressive tumors (over-diagnosis) followed by unnecessary treatment (over-treatment) and morbidity related to complications. [12-13].

PHI as a combination of all three markers, showed the superiority in increasing the sensitivity and specificity in diagnoses of PCa. This study showed the AUC ROC curve for PHI, %p2PSA, and tPSA was

0.954, 0.948, and 0.656, respectively. PHI showed the highest sensitivity of 85.7% (compared with tPSA 61.9% and p2PSA 66.7%), and highest NPV of 91.57% (compared with %p2PSA 80.0% and tPSA 72.8%),. The highest specificity was observed for PHI - 96.20% followed by %p2PSA - 94.94%. A lower specificity was noted for tPSA 59.5%. The AUC for PHI was 0.954, which is a comparable value with the data from other authors with similar inclusion criteria, such as Lughezzani G, Lazzeri M, *et al.* [14].

Data from the meta-analysis (including 12 studies) of Filella *et al.* showed AUCs for PHI between 0.703 and 0.77, which increases the specificity for prostate cancer detection and reduces the number of unnecessary biopsies, maintaining a high cancer detection rate [15].

Boegemann *et al.*, in their multicenter study, showed that in comparison with tPSA, %fPSA, and %pro2PSA, PHI had a superior diagnostic performance for detecting prostate cancer in men with tPSA in the range 1.6–8.0 ng/mL.[16].

Using a PHI threshold for biopsy of 28.6 led to a 90% sensitivity and avoidance of 30% unnecessary biopsies, with indolent or no prostate cancer,[17] which is quite consistent to our study.

This is also consistent with the observations made by Catalona *et al.* [18] showing a 26% specificity for the PHI at 90% sensitivity with the cut-off as low as 24, according to our study with specificity of 29.11% for the PHI at 100% sensitivity with the cut-off 26.99. The authors also concluded that most studies do not state recommended cut-offs. In addition, the European Association of Urology (EAU) guidelines published in 2016 suggested that the PHI could be used as an additional diagnostic option for men with a serum PSA level between 2 and 10 ng/mL and a negative DRE [19].

As a specific biomarker that could increase predictive validity and risk stratification, PHI is needed to identify patients who may have PCa and reduce morbidity due to unnecessary diagnosis and treatment. PHI showed higher predictive performance in the detection of PCa compared to standard reference methods, and they were better able to distinguish aggressive ( $GS \geq 7$ ) from clinically indolent PCa.

As the PHI increased, the ratio of high GS also increased.  $GS \geq 7$  began to appear in groups with  $PHI \geq 36.0$ , particularly for GS 8 and 9 patients, who were distributed only in the groups with  $PHI \geq 54.99$ . In, our study for the PHI levels (36-54.99) only 23.08 of patients had Gleason score  $\geq 7$ . In patients with PHI levels  $>55$ , 76.92% of patients had Gleason score  $\geq 7$ . Wang *et al.*, in a meta-analysis found significantly higher PHI values observed in patients with  $GS \geq 7$  ( $PHI \geq 60$ ) compared with  $GS < 7$  ( $PHI < 53$ ;  $p = 0.0018$ ). [20].

Median PHI for patients with Gleason score  $\geq 7$  in our study was 79.43(59.4-103.1) vs 63.61(45.89-100.1) for group with  $GS < 7$ . This clinically important finding was also confirmed by Abrate *et al.*[21] and Filella *et al.*,[22] who reported significantly higher PHI (median: 69.75 vs. 48.04) values in patients with prostate cancer, ( $p < 0.001$ ) confirmed with a prostate biopsy with  $GS \geq 7$ .

Tosoian *et al.* reported similar findings with PHI testing in their large academic center practice at Johns Hopkins University. A prospective registry of 345 men receiving a PHI result was compared to a contemporary cohort of 1318 men who did not undergo PHI testing.

Their comparative analysis showed that PHI testing reduced the rate of biopsy procedures performed without changing the frequency of higher-grade cancers detected. Overall, 39% of men in their registry underwent a biopsy when PHI was included in the assessment, representing a 9% reduction in the rate of prostate biopsy procedures performed compared to the control group (48%,  $P < 0.001$ ). 91% of men with PHI 55+ had Gleason score  $\geq 7$  cancers. [23].

Many studies reported similarities compared to our study. Sanda and colleagues evaluated PHI in a group of 658 men with PC. The authors reported that PHI improved the prediction of high-grade PC in a group with the range of PSA from 4 to 10 ng/mL.

The PHI correlated significantly with the bioptic GS [24]. One of the largest projects in recent times has been the Multicentric European Study (PROMETHEUS), which confirmed that PHI is one of the strongest predictors of PC which correlates with biopsy GS.

The aim of this study was to investigate the PHI as a marker for tumor aggressiveness in prostate biopsy and the optimization of correct indications for treatment options [25]. In spite of that, all studies agreed that PHI was more superior than current standard biomarkers and may potentially reduce unnecessary prostate biopsies and biopsy-related morbidities. [26, 27, 28, 29].

The main limitation of this study was the relatively small sample size. The examined patients do not represent a screening population. It is done in a single secondary referral center and patients were enrolled due to the increased suspicion of csPCa. The number of examined patients is also limited. To conclusively prove that PHI is a superior marker, larger prospective studies are needed. This issue is clinically relevant.

### Conclusions

In conclusion, the new PHI test outperforms its individual components of total, free and (-2)proPSA for the identification of clinically significant prostate cancer. PHI may be useful as part of a multivariable approach to reduce prostate biopsies and overdiagnosis.

### Abbreviations

PHI- prostate health index; fPSA-free PSA; PCa-prostate cancer; nonPCa-no significant prostate cancer; PSA-prostate-specific antigen, pPSA: proPSA; p2PSA: [-2]proPSA; DRE-digital rectal examination; CI-confidence interval; AUC-area under curve; TRUS-transrectal ultrasound; Gleason score-GS; FDA-Federal Drug Administration; (EAU)- European Association of Urology; csPCa.- clinical significant PCa

### References

1. Chen R, Ren S, Yiu MK, et al. Prostate cancer in Asia: A collaborative report. *Asian J Urol.* 2014; 1(1): 15-29.
2. <https://www.worldlifeexpectancy.com/macedonia-prostate-cancer> (авторот, насловот, годината, волуменот)
3. Fuchsova R, Topolcan O, Windrichova J, et al. PHI in the early detection of prostate cancer. *Anticancer Res.* 2015; 35(9):4855-4857.
4. Wilt TJ, Jones KM, Barry MJ, et al. Follow-up of prostatectomy versus observation for early prostate cancer. *N Engl J Med.* 2017; 377(2):132-142. doi:10.1056/NEJMoa1615869
5. Adhyam M, Gupta AK. A Review on the Clinical Utility of PSA in Cancer Prostate. *Indian J Surg Oncol.* 2012; 3(2): 120-9
6. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level  $\leq 4.0$  ng per Milliliter. *N Engl J Med.* 2004; 350(22): 2239-46
7. Mikolajczyk, S., Catalona, W., Evans, C., Linton, H., Millar, L., Marker, K. et al. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. *Clin Chem* 2004; 50: 1017–1025.
8. Sokoll, L., Sanda, M., Feng, Z., Kagan, J., Mizrahi, I., Broyles, D. et al. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. *Cancer Epidemiol Biomarkers Prev* 2010; 19: 1193–1200
9. Catalona, W., Partin, A., Sanda, M., Wei, J., Klee, G., Bangma, C. et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. *J Urol* 2011; 185: 1650–1655.
10. Lazzeri M, Haese A, de la Taille A, et al. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study. *Eur Urol.* 2013; 63:986. [PubMed] [Google Scholar]
11. Hatakeyama S, Yoneyama T, Tobisawa Y, Ohyama C. Recent progress and perspectives on prostate cancer biomarkers. *Int J Clin Oncol.* 2017;22(2):214–21.

12. Borghesi M, Ahmed H, Nam R, Schaeffer E, Schiavina R, Taneja S, Weidner W, Loeb S. Complications after systematic, random, and image-guided prostate biopsy. *Eur Urol*. 2017;71(3):353–65.
13. Heijnsdijk EA, Wever EM, Auvinen A, Hugosson J, Ciatto S, Nelen V, Kwiatkowski M, Villers A, Paez A, Moss SM, et al. Quality-of-life effects of prostate-specific antigen screening. *N Engl J Med*. 2012;367(7):595–605.
14. Lughezzani G, Lazzeri M, Larcher A, Lista G, Scattoni V, Cestari A, Buffi NM, Bini V and Guazzoni G: Development and internal validation of a prostate health index-based nomogram for predicting prostate cancer at extended biopsy. *J Urol* 2012; 188: 1144-1150
15. Filella X and Giménez N: Evaluation of [-2] pro PSA and Prostate Health Index (phi) for the detection of prostate cancer:a systematic review and meta-analysis. *Clin Chem Lab Med* 2013; 51(4): 729-739
16. Boegemann M, Stephan C, Cammann H, Vincendeau S, Houlgatte A, Jung K, et al. The percentage of prostatespecific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years. *BJU Int* 2016 Jan;117(1):72-79
17. Loeb S, Sanda MG, Broyles DL, et al. The prostate health index selectively identifies clinically significant prostate cancer. *J Urol* 2015;193:1163-9. 10.1016/j.juro.2014.10.121 [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
18. Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, Slawin KM, Marks LS, Loeb S, Broyles DL, Shin SS, Cruz AB, Chan DW, Sokoll LJ, Roberts WL, van Schaik RH and Mizrahi IA: A multicenter study of [-2]pro-prostate-specific antigen combined with prostate-specific antigen and free prostate-specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate-specific antigen range. *J Urol* 2011; 185: 1650-165
19. Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. *Eur Urol* 2017;71:618e29.
20. Wang W, Wang M, Wang L, Adams TS, Tian Y, Xu J. Diagnostic ability of %p2PSA and prostate health index for aggressive prostate cancer: a meta-analysis. *Sci Rep* 2014 May;4:5012.
21. Abrate A, Lughezzani G, Gadda GM, Lista G, Kinzikееva E, Fossati N, et al. Clinical use of [-2]proPSA (p2PSA) and its derivatives (%p2PSA and Prostate Health Index) for the detection of prostate cancer: a review of the literature. *Korean J Urol* 2014 Jul;55(7):436-445.
22. Filella X, Foj L, Augé JM, Molina R, Alcover J. Clinical utility of %p2PSA and prostate health index in the detection of prostate cancer. *Clin Chem Lab Med* 2014 Sep;52(9):1347-1355.
23. Tosoian JJ, Druskin SC, Andreas D, Mullane P, Chappidi M, Joo S, et al. Use of the Prostate Health Index for detection of prostate cancer: results from a large academic practice. *Prostate Cancer Prostatic Dis*. 2017;20:228–33
24. Sanda M, Wei J, Broyles D, et al. Evaluation of the Prostate Health Index (PHI) for improving prostate cancer detection and identification of clinically significant prostate cancer in the 4 to 10 ng/mL PSA range. In: *Proceedings of American Urological Association Annual Meeting San Diego, Rev Urol*.2013; 02:2474
25. Fossati N, Buffi NM, Haese A, et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer: results from a Multicentric European Prospective Study. *Eur Urol*. 2016; 68(1):132–138. [[PubMed](#)] [[Google Scholar](#)]
26. Ito K, Miyakubo M, Sekine Y, et al. Diagnostic significance of [-2]pro-PSA and prostate dimension adjusted PSA-related indices in men with total PSA in the 2.0-10.0ng/mL range. *World J Urol*. 2013; 31(2): 305-11.
27. Tan LG, Tan YK, Tai BC, et al. Prospective validation of %p2PSA and the Prostate Health Index, in prostate cancer detection in initial prostate biopsies of Asian men, with total PSA 4-10 ng ml1. *Asian J Androl*. 2017; 19(3): 286-90

28. Ng CF, Chiu PKF, Lam NY, Lam HC, Lee KWM, Hou SSM. The Prostate Health Index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4-10ng/mL. *Int Urol Nephrol*. 2014; 46(4): 711-7.
29. Na R, Ye D, Liu F, et al. Performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and the prostate health index (PHI) in a Chinese hospital-based biopsy population. *Prostate*. 2014; 74(15): 1569-75.